Aslan’s insiders

What Asian biotechs considering NASDAQ could learn from Aslan’s listing

A disappointing offering on NASDAQ by Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) looks to be the consequence of Taiwan exchange rules that prevented more robust insider participation. So even though big names such as Morningside and Temasek bought 60% of the deal, excluded insiders meant NASDAQ investors saw only that the overall insider stake

Read the full 531 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE